SCHEMBL6765103

SCHEMBL6765103

O=C(O)c1ccc2c(c1)CN(Cc1ccncc1)C2=O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HDAC1 Q13547 5/20 0.45
HDAC4 P56524 2/20 0.45
HDAC6 Q9UBN7 2/20 0.45
HPGD P15428 1/20 0.45
ALDH1A1 P00352 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.42
ENPP2 Q13822 1/20 0.41
DHPS P49366 1/20 0.41
SRD5A2 P31213 2/20 0.40
ITGB3 P05106 1/20 0.40
ITGA2B P08514 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
SRD5A1 P18405 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA9 Q16790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31409508 0.83 CYP19A1 (0.50) MEN1KMT2AHDAC1HDAC4HDAC6
SCHEMBL6765858 0.81 MEN1 (0.46) MEN1KMT2AHDAC1HDAC6HPGD
SCHEMBL7979501 0.81 L3MBTL1 (0.53) MEN1KMT2AHDAC1HDAC4HDAC6
SCHEMBL446687 0.80 SRD5A1 (0.49) MEN1KMT2AHDAC1HDAC4HDAC6
SCHEMBL23387571 0.78 POLB (0.55) MEN1KMT2AHPGDALDH1A1SRD5A2
SCHEMBL2065219 0.77 HDAC1 (0.59) MEN1KMT2AHDAC1HDAC4HDAC6
SCHEMBL12446495 0.77 HDAC1 (0.49) MEN1KMT2AHDAC1HDAC4HDAC6
SCHEMBL1065002 0.76 MEN1 (0.69) MEN1KMT2AHDAC1HDAC4HDAC6
SCHEMBL6767196 0.76 MEN1 (0.46) MEN1KMT2AHDAC1HDAC6ALDH1A1
SCHEMBL6767486 0.75 MEN1 (0.49) MEN1KMT2AHDAC1HDAC4HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US claimed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis NAHRA JOE (US) 2004-02-26 US disclosed
WO-2004014365-A1 PHTHALIMIDE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038973-A1 Treating osteoarthritis or rheumatoid arthritis MMP13, MMP11, MMP9 MEN1 2463/4885KMT2A 4041/4885HDAC1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.